CATX Insider Trading

Insider Ownership Percentage: 3.52%
Insider Buying (Last 12 Months): $58,050,439.60
Insider Selling (Last 12 Months): $0.00

Perspective Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Perspective Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Perspective Therapeutics Share Price & Price History

Current Price: $13.36
Price Change: Price Increase of +0.54 (4.21%)
As of 07/25/2024 04:26 PM ET

This chart shows the closing price history over time for CATX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Perspective Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/17/2024Jonathan Robert HuntCFOBuy1,800$9.81$17,658.0035,971View SEC Filing Icon  
6/14/2024Lori A WoodsDirectorBuy4,587$10.90$49,998.30159,985View SEC Filing Icon  
6/13/2024Johan M SpoorCEOBuy10,000$11.70$117,000.0013,757View SEC Filing Icon  
6/3/2024Lori A WoodsDirectorBuy3,424$14.60$49,990.40155,398View SEC Filing Icon  
5/31/2024Jonathan Robert HuntCFOBuy2,500$14.00$35,000.0034,171View SEC Filing Icon  
5/31/2024Robert F Williamson IIIDirectorBuy5,500$13.80$75,900.0042,379View SEC Filing Icon  
5/29/2024Robert F Williamson IIIDirectorBuy3,003$13.30$39,939.9036,879View SEC Filing Icon  
3/6/2024Lantheus Alpha Therapy, LlcMajor ShareholderBuy6,043,103$9.50$57,409,478.5011,677,339View SEC Filing Icon  
1/29/2024Robert F Williamson IIIDirectorBuy2,526$6.40$16,166.4021,155View SEC Filing Icon  
1/25/2024Robert F Williamson IIIDirectorBuy2,213$4.90$10,843.707,567View SEC Filing Icon  
1/24/2024Markus PuhlmannInsiderBuy28,000$5.00$140,000.00137,542View SEC Filing Icon  
12/21/2023Robert F Williamson IIIDirectorBuy366$3.30$1,207.80366View SEC Filing Icon  
12/18/2023Jonathan Robert HuntCFOBuy12,500$2.60$32,500.0031,671View SEC Filing Icon  
12/18/2023Markus PuhlmannInsiderBuy6,041$2.60$15,706.6069,542View SEC Filing Icon  
12/18/2023Robert F Williamson IIIDirectorBuy1,000$2.60$2,600.001,000View SEC Filing Icon  
12/15/2023Markus PuhlmannInsiderBuy13,500$2.70$36,450.0063,500View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Perspective Therapeutics (NYSE:CATX)

54.66% of Perspective Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CATX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Perspective Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/20/2024Virtu Financial LLC115,762$0.14M0.0%N/A0.019%Search for SEC Filing on Google Icon
5/16/2024Janus Henderson Group PLC13,089,476$15.51M0.0%N/A2.230%Search for SEC Filing on Google Icon
5/15/2024Baker BROS. Advisors LP149,787$0.18M0.0%-98.0%0.026%Search for SEC Filing on Google Icon
5/15/2024Affinity Asset Advisors LLC5,100,000$6.07M0.8%N/A0.869%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.17,780,106$21.16M0.0%+34.6%3.029%Search for SEC Filing on Google Icon
5/8/2024Bleakley Financial Group LLC33,570$40K0.0%N/A0.006%Search for SEC Filing on Google Icon
5/3/2024RIA Advisory Group LLC106,853$0.13M0.1%+1,313.4%0.018%Search for SEC Filing on Google Icon
4/26/2024ZWJ Investment Counsel Inc.22,000$26K0.0%N/A0.004%Search for SEC Filing on Google Icon
4/24/2024Simplicity Wealth LLC33,570$40K0.0%N/A0.006%Search for SEC Filing on Google Icon
1/22/2024Perkins Capital Management Inc.700,000$0.28M0.2%-73.8%0.249%Search for SEC Filing on Google Icon
1/11/2024Taylor & Morgan Wealth Management LLC625,000$0.25M0.2%+8.7%0.223%Search for SEC Filing on Google Icon
11/8/2023HighTower Advisors LLC1,147,038$0.31M0.0%N/A0.409%Search for SEC Filing on Google Icon
11/2/2023Perkins Capital Management Inc.2,671,644$0.73M0.7%N/A0.952%Search for SEC Filing on Google Icon
10/24/2023Bank of New York Mellon Corp154,238$42K0.0%N/A0.055%Search for SEC Filing on Google Icon
10/16/2023Wealth Effects LLC110,000$30K0.0%N/A0.039%Search for SEC Filing on Google Icon
10/5/2023Taylor & Morgan Wealth Management LLC575,000$0.16M0.1%N/A0.205%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
Read More on Perspective Therapeutics

Today's Range

Now: $13.36
Low: $12.82
High: $13.62

50 Day Range

MA: $12.43
Low: $9.51
High: $16.90

52 Week Range

Now: $13.36
Low: $2.05
High: $19.05

Volume

703,180 shs

Average Volume

604,791 shs

Market Capitalization

$831.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Who are the company insiders with the largest holdings of Perspective Therapeutics?

Perspective Therapeutics' top insider shareholders include:
  1. Lantheus Alpha Therapy, Llc (Major Shareholder)
  2. Lori A Woods (Director)
  3. Markus Puhlmann (Insider)
  4. Robert F Williamson III (Director)
  5. Jonathan Robert Hunt (CFO)
  6. Johan M Spoor (CEO)
Learn More about top insider investors at Perspective Therapeutics.